The current understanding of PARPi resistance is mainly focused on tumor cell-intrinsic mechanisms, including the cellular availability of PARPi, reversion mutations in BRCA1/2, restoration of HR or PARylation, and DNA replication fork protection15,46,47. This evidence concerns the gene BRCA1 and neoplasm.